TELANGIECTASIA, HEREDITARY HEMORRHAGIC

Clinical trials for TELANGIECTASIA, HEREDITARY HEMORRHAGIC explained in plain language.

Never miss a new study

Get alerted when new TELANGIECTASIA, HEREDITARY HEMORRHAGIC trials appear

Sign up with your email to follow new studies for TELANGIECTASIA, HEREDITARY HEMORRHAGIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Completed 1

New hope for controlling debilitating nosebleeds in rare disease

Symptom relief Recruiting now

This study is testing whether a drug called nintedanib can reduce the frequency and severity of nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT), a rare genetic disorder. About 48 adult participants with moderate to severe nosebleeds will be randomly assigned…

Matched conditions: TELANGIECTASIA, HEREDITARY HEMORRHAGIC

Phase: PHASE2 • Sponsor: Dr. Romain Lazor • Aim: Symptom relief

Last updated Mar 30, 2026 14:30 UTC

TELANGIECTASIA, HEREDITARY HEMORRHAGIC

Get alerted when new TELANGIECTASIA, HEREDITARY HEMORRHAGIC trials appear

New hope for controlling debilitating nosebleeds in rare disease